Meeting
2022 ASCO Annual Meeting
Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.
Authors
Scott Moerdler
Department of Pediatrics, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Scott Moerdler , Arlene Naranjo , Sheena Tenney , Rochelle Bagatell , Alice L. Yu , Wendy B. London
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT00026312
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10043)
DOI
10.1200/JCO.2022.40.16_suppl.10043
Abstract #
10043
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Single-agent activity of the anti-GD2 antibody dinutuximab beta given as a long-term infusion in relapsed and refractory neuroblastoma (APN311-304).
First Author: Holger N. Lode
Poster
2022 ASCO Annual Meeting
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.
First Author: Javier E. Oesterheld
Poster
2020 ASCO Virtual Scientific Program
The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy: Results of 2 consecutive studies in a single referral institution.
First Author: Jaume Mora
Poster
2020 ASCO Virtual Scientific Program
Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.
First Author: Ami Vijay Desai